KR20080035853A - A composition having protective function from alcoholic hangover comprising dropwort extract as active ingredient and functional health food using the same - Google Patents
A composition having protective function from alcoholic hangover comprising dropwort extract as active ingredient and functional health food using the same Download PDFInfo
- Publication number
- KR20080035853A KR20080035853A KR1020060102442A KR20060102442A KR20080035853A KR 20080035853 A KR20080035853 A KR 20080035853A KR 1020060102442 A KR1020060102442 A KR 1020060102442A KR 20060102442 A KR20060102442 A KR 20060102442A KR 20080035853 A KR20080035853 A KR 20080035853A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- hangover
- composition
- group
- buttercup
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 66
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 235000013402 health food Nutrition 0.000 title claims abstract description 16
- 239000004480 active ingredient Substances 0.000 title abstract description 10
- 235000016622 Filipendula ulmaria Nutrition 0.000 title abstract 4
- 244000061544 Filipendula vulgaris Species 0.000 title abstract 4
- 235000009009 Filipendula vulgaris Nutrition 0.000 title abstract 4
- 206010001623 Alcoholic hangover Diseases 0.000 title 1
- 230000009993 protective function Effects 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 148
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 40
- 206010019133 Hangover Diseases 0.000 claims abstract description 38
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000002904 solvent Substances 0.000 claims abstract description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims abstract description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 26
- 238000000605 extraction Methods 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 9
- 241000208173 Apiaceae Species 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 230000008030 elimination Effects 0.000 claims description 2
- 238000003379 elimination reaction Methods 0.000 claims description 2
- KTUQUZJOVNIKNZ-UHFFFAOYSA-N butan-1-ol;hydrate Chemical group O.CCCCO KTUQUZJOVNIKNZ-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 235000013305 food Nutrition 0.000 abstract description 13
- 239000000654 additive Substances 0.000 abstract description 4
- 230000000996 additive effect Effects 0.000 abstract description 4
- 241000196324 Embryophyta Species 0.000 abstract 2
- 241000218206 Ranunculus Species 0.000 description 45
- 239000008280 blood Substances 0.000 description 44
- 210000004369 blood Anatomy 0.000 description 44
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 36
- 239000002034 butanolic fraction Substances 0.000 description 15
- 230000037396 body weight Effects 0.000 description 11
- 239000003814 drug Substances 0.000 description 9
- RYKKQQUKJJGFMN-HVDRVSQOSA-N 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;(2s)-5-oxopyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCC(=O)N1.CC1=NC=C(CO)C(CO)=C1O RYKKQQUKJJGFMN-HVDRVSQOSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- CZFNXFXZXWDYMZ-UHFFFAOYSA-N [5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-oxochromen-3-yl] hydrogen sulfate Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OS(O)(=O)=O)=C1 CZFNXFXZXWDYMZ-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 5
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- -1 FLUIDEXTRACTS Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000004149 ethanol metabolism Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000011514 reflex Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 240000008881 Oenanthe javanica Species 0.000 description 2
- 235000000365 Oenanthe javanica Nutrition 0.000 description 2
- 241000283977 Oryctolagus Species 0.000 description 2
- 240000009164 Petroselinum crispum Species 0.000 description 2
- 241000218201 Ranunculaceae Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000002038 ethyl acetate fraction Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000002044 hexane fraction Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000011197 perejil Nutrition 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000244342 Ostericum Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229930010796 primary metabolite Natural products 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
Abstract
Description
도 1은 뉴질랜드 토끼(New zealand white)에 미나리 열수 추출물을 에탄올과 함께 정맥 투여한 후 혈중 에탄올 농도의 변화를 도표화하여 나타낸 것이다.FIG. 1 is a chart showing the change in blood ethanol concentration after intravenous administration of Buttercup hot water extract to New Zealand rabbit (New zealand white).
도 2는 미나리 열수 추출물을 n-헥산, 메틸렌클로라이드, 에틸아세테이트, n-부탄올 등으로 2차 분획한 후, ICR 마우스에 추출물을 에탄올과 함께 경구섭취시키고 혈중 에탄올 농도의 변화를 도표화하여 나타낸 것이다.Figure 2 is a secondary fraction of the hot water extract of Buttercup extract with n-hexane, methylene chloride, ethyl acetate, n-butanol, etc., ICR mice orally ingested the extract with ethanol, and shows the change in blood ethanol concentration chart.
도 3은 미나리 열수 추출물의 n-부탄올 2차 분획 추출물을 ICR 마우스에 에탄올과 함께 경구섭취시켰을 때 n-부탄올 추출물의 양에 따른 혈중 에탄올 제거 효과를 도표화하여 나타낸 것이다.Figure 3 is a graphical representation of the effect of removing the ethanol in blood according to the amount of n-butanol extract when n-butanol secondary fraction extract of Buttercup hot water extract orally with ethanol in ICR mice.
도 4는 ICR 마우스에 미나리 열수 추출물 및 이의 n-부탄올 2차 분획 추출물을 에탄올과 함께 경구섭취시켰을 때 혈중 에탄올 농도(4a) 및 혈중 아세트알데히드 농도(4b)에 미치는 영향을 각각 그래프로 나타낸 것이다.FIG. 4 is a graph showing the effects of oral intake of Buttercup hot water extract and its n-butanol secondary fraction extract on ICR mice on blood ethanol concentration (4a) and blood acetaldehyde concentration (4b), respectively.
본 발명은 미나리 추출물을 유효성분으로 함유하는 숙취해소용 조성물 및 이를 이용한 기능성 건강식품에 관한 것으로, 더욱 상세하게는 미나리의 열수 추출물 및 그 분획의 추출물을 유효성분으로 하는 숙취해소용 조성물을 제조하고 이를 이용하여 기능성 건강식품을 제조함으로써 혈중 알코올 및 아세트알데히트 대사를 촉진시켜 숙취에 따른 생리학적 부작용을 경감시켜 숙취를 치료하거나 또는 예방하는 효과를 가지는 식품조성물에 관한 것이다. The present invention relates to a hangover releasing composition containing the buttercup extract as an active ingredient and a functional health food using the same, and more particularly to preparing a hangover releasing composition comprising the extract of the hot water extract and its fraction of the buttercup and as an active ingredient The present invention relates to a food composition having the effect of treating or preventing a hangover by promoting the metabolism of alcohol and acetaldehyde in blood to reduce the physiological side effects of the hangover by preparing a functional health food using the same.
일반적으로, 알코올은 공복시에는 섭취된 후 30분, 식이와 함께일 경우에는 1시간 경에 혈중 최고 농도를 나타낸다고 한다. 섭취된 알코올은 위장에서도 소량 흡수될 수 있으나 소장으로 이동시 순식간에 흡수가 이루어지므로 알코올의 흡수 속도를 결정짓는 요소는 알코올의 위 배출시간에 의하여 결정된다. 알코올의 위 배출 시간은 함께 섭취한 음식물의 종류 및 양 등에 따라 다를 수 있다. 위장관에서 혈액으로 흡수된 알코올은 중추 및 말초적인 여러 가지 생리적인 반응을 일으키게 되며, 이러한 작용은 알코올 그 자체라기 보다는 일차 대사산물인 아세트알데히드(acetaldehyde)에 의하여 일어나게 된다(Goodman and Gilman's The pharmacological bassis of therapeutics, p 384, 6th ed., 1980). 알코올의 분해는 주로 간에서 이루어진다. 그 첫번째 과정은 간 세포에 있는 알코올 탈수소효소(alcohol dehydrogenase)에 의하여 혈중 알코올이 아세트알데히드로 변환되며 이 물질은 다시 간에 있는 아세트알데히드 탈수소효소(acetaldehyde dehydrogenase)에 의하여 초산(acetic acid)으로 분해된 후 물과 이산화탄소로 최종 대사된 다(Goodman and Gilman's The pharmacological bassis of therapeutics, p 383, 6th ed., 1980). In general, alcohol is said to have the highest concentration in the
알코올에 의한 생리적인 반응은 전술한 바와 같이 혈중의 아세트알데히드에 의하여 주로 일어나게 되며 특징적인 것으로는 흥분, 말초혈관 확장, 두통 등을 초래하게 되며, 음주 후 불유쾌한 생리적인 반응을 통칭하여 숙취라고 한다. 따라서 숙취의 정도를 결정짓는 주 요소는 아세트알데히드 탈수소효소의 양이나 활성도이며 이는 인종이나 개인에 따른 차이가 많다고 알려져 있다. 예를 들어 동양인은 백인에 비하여 아세트알데히드 탈수소효소 II형이 부족하여 백인에 비하여 상대적으로 숙취가 심한 것으로 알려져 있다. As mentioned above, the physiological reaction by alcohol is mainly caused by acetaldehyde in the blood, which is characterized by excitement, peripheral vasodilation, headache, etc., and the unpleasant physiological reaction after drinking is called hangover. . Therefore, the main factor that determines the degree of hangover is the amount or activity of acetaldehyde dehydrogenase, which is known to be different according to race or individual. For example, Asians lack acetaldehyde dehydrogenase type II compared to Caucasians and are known to have a severe hangover compared to Caucasians.
알코올 자체와 아세트알데히드는 세포막에 손상을 주어 세포를 죽게 할 수 있다. 그 중 만성적인 알코올 섭취는 알코올에 취약한 신경세포를 죽게 하는 작용이 있으므로 알코올성 치매, 정신병 등을 유발할 수도 있다(Goodman and Gilman's The pharmacological bassis of therapeutics, p 381, 6th ed., 1980).Alcohol itself and acetaldehyde can damage cell membranes and cause them to die. Among them, chronic alcohol intake may kill nerve cells that are vulnerable to alcohol and may cause alcoholic dementia and psychosis (Goodman and Gilman's The pharmacological bassis of therapeutics, p 381, 6th ed., 1980).
최근 들어 알코올의 해독을 줄이기 위한 많은 물질에 대한 연구와 실험이 이루어졌으며 냉전시대에 소련의 KGB가 사용한 것으로 알려진 RU-21는 알코올탈수소효소의 작용을 억제시켜 아세트알데히드의 혈중 농도를 천천히 증가시킴으로서 알코올의 뇌 기능 억제 및 신체반응을 적게 나타나게 함으로서 상대적으로 적은 숙취 현상을 보이도록 고안된 물질이다. 그러나 RU-21 는 알코올탈수소효소의 작용을 억제되었기 때문에 혈중 알코올 농도는 더 오랫동안 유지되므로 알코올 그 자체에 의한 독 작용은 더 크지는 단점이 있다. 따라서 바람직한 숙취해소제는 알코올 그 자 체의 해독을 줄이기 위해서라도 알코올탈수소효소와 아세트알데히드 탈수소효소의 작용을 모두 증가시키는 작용을 가진 것이 바람직하다.Recently, many studies and experiments have been conducted to reduce the detoxification of alcohol. RU-21, which was known to be used by the Soviet KGB during the Cold War, suppresses the action of alcohol dehydrogenase and slowly increases the concentration of acetaldehyde in the blood. It is designed to show relatively low hangover phenomenon by suppressing brain function and making body reaction less. However, since RU-21 inhibits the action of alcohol dehydrogenase, blood alcohol concentration is maintained for a longer time, so the poisoning effect of alcohol itself is greater. Therefore, it is preferable to have a function of increasing the action of both alcohol dehydrogenase and acetaldehyde dehydrogenase in order to reduce the detoxification of alcohol itself.
이에, 본 발명자들은 미나리를 열수로 중탕하여 추출한 후 상기 추출물을 유효성분으로 포함하는 조성물이 생체 내에서 알코올탈수소효소와 아세트알데히드 탈수소효소의 작용을 모두 증가시켜 혈중 에탄올 및 혈중 아세트알데히드 농도를 경감시킴으로써 숙취해소 개선에 효능이 있음을 확인함으로써 본 발명을 완성하였다.Therefore, the present inventors extract the water by boiling water in the buttercups, the composition containing the extract as an active ingredient to increase the action of both alcohol dehydrogenase and acetaldehyde dehydrogenase in vivo to reduce the blood ethanol and blood acetaldehyde concentration The present invention was completed by confirming the efficacy in improving hangover relief.
본 발명의 목적은 미나리 추출물을 유효성분으로 포함하는 숙취해소용 조성물 및 이를 포함하는 숙취현상의 치료 및 예방에 이용될 수 있는 약제 및 기능성 건강식품을 제공하는 것이다.It is an object of the present invention to provide a hangover relief composition comprising the buttercup extract as an active ingredient, and a pharmaceutical and functional health food that can be used for the treatment and prevention of the hangover including the same.
본 발명은 상기한 바와 같은 제반 문제점들을 감안하여 안출된 것으로, 그 목적은 천연식품의 특정성분을 추출하고 이를 일정량 유효성분으로 포함하도록 함으로써 생체에 무해하여 부작용이 전혀 없으면서도 숙취해소 효과를 가지는 숙취해소용 조성물을 제공하는 데 있다.The present invention has been made in view of the above-mentioned problems, the purpose of which is to extract a specific ingredient of natural foods and to include it as a certain amount of active ingredient harmless to the living body and has no hangover effect without hangover at all hangover It is to provide a composition for elimination.
이하, 본 발명의 구성 및 작용을 설명한다.Hereinafter, the configuration and operation of the present invention.
상기 목적을 달성하기 위하여, 본 발명은 미나리 추출물을 유효성분으로 포함하는 숙취해소용 조성물을 제공한다.In order to achieve the above object, the present invention provides a hangover relief composition comprising the buttercup extract as an active ingredient.
또한, 본 발명은 미나리 추출물을 원료로 하는 숙취해소용 조성물의 제조방법을 제공한다.The present invention also provides a method for producing a hangover relief composition using the buttercup extract as a raw material.
아울러, 본 발명은 상기 조성물과 약학적으로 허용가능한 담체 또는 식품학적으로 허용가능한 식품보조 첨가제를 포함하는 숙취현상을 치료하거나 또는 예방할 수 있는 약제 및 기능성 건강식품을 제공한다.In addition, the present invention provides a medicament and functional health food that can treat or prevent the hangover including the composition and a pharmaceutically acceptable carrier or a food acceptable additive.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 숙취해소용 조성물은 미나리과 식물의 전초 또는 지상부를 열수로 추출함으로써 수득하였다. 이때, 상기 미나리과 식물로는 오스테리아쿰 코리아눔 (Ostericum coreanum), 오에난테 자바니카(Oenanthe javanica), 오에난테 스톨로니페라 (Oenanthe stolonifera) 등 모든 미나리과 식물을 포함할 수 있다.The hangover composition of the present invention was obtained by extracting the outpost or ground part of the apiaceae with hot water. At this time, the asteraceae plants include Ostericum coreanum , Oenanthe Javanica javanica ), Oenante Stallonifera ( Oenanthe stolonifera ), including all apiaceae plants.
또한, 본 발명에서는 상기 미나리과 식물의 전초 또는 지상부를 이용하여 물, 유기용매 또는 이들의 혼합용매를 추출용매로 하여 유효성분을 추출한 후 여과하거나, 경우에 따라, 이를 농축하여 사용하는 것이 바람직하다. 이때, 상기 추출용매로는 물, 탄소수 1(C1) 내지 탄소수 4(C4)의 저가 알코올 또는 알코올 희석수를 사용할 수 있으나, 이에 제한되는 것은 아니다. 상기 저가 알코올은 에탄올, 메탄올, n-부탄올, n-프로판올 및 이소프로판올 중 어느 하나를 사용할 수 있으나, 이에 제한되는 것은 아니며, 바람직하게는 n-부탄올을 사용할 수 있다. 특히, 본 발명에 있어서는 미나리를 물로 50~110℃에서, 바람직하게는 80~100℃에서, 1시간 내지 1일간, 바람직하게는 2~3시간 환류 추출하여 미나리 추출물을 제조하였다. 상기와 같이 미나리를 열수로 환류 추출한 후, 지표물질인 페르시카린(persicarin)의 함량을 HPLC로 분석한 결과, 페르시카린 함량은 0.23%이었다.In addition, in the present invention, water, an organic solvent or a mixed solvent thereof is used as an extraction solvent using an outpost or ground part of the apiaceae plant, and then the active ingredient is extracted and filtered. In this case, the extraction solvent may be water, a low-cost alcohol or dilution of alcohol having 1 (C1) to 4 carbon atoms (C4), but is not limited thereto. The low cost alcohol may be any one of ethanol, methanol, n-butanol, n-propanol, and isopropanol, but is not limited thereto. Preferably, n-butanol may be used. In particular, in the present invention, the buttercup extract is prepared by reflux extraction at 50 to 110 ° C with water, preferably at 80 to 100 ° C for 1 hour to 1 day, and preferably 2 to 3 hours. After extracting the buttercups under reflux with hot water as described above, the content of persicarin as an indicator was analyzed by HPLC, and the persicarin content was 0.23%.
또한, 상기 미나리 열수 추출물은 n-헥산, 메틸렌클로라이드, 아세톤, 에틸아세테이트 및 n-부탄올로 이루어진 군 중에서 선택된 1종 이상의 용매를 사용하여 추가적으로 분획할 수 있다. 상기 추출물 또는 추출물에 추가적인 용매를 사용하여 분획한 분획물의 제조온도는 20 내지 50℃일 수 있으나, 이에 제한되는 것은 아니다. 추출시간은 특별히 제한되는 것은 아니나, 10분 내지 1일 이내에 추출하는 것이 바람직하며, 추출용 기기로는 통상의 추출기기, 초음파분쇄추출기 또는 분획기를 이용할 수 있다. 이렇게 제조된 추출물은 열풍건조, 감압건조 또는/및 동결건조하여 용매를 제거할 수 있으나, 이에 제한되는 것은 아니며, 바람직하게는 감압건조하여 용매를 제거할 수 있다. In addition, the buttercup hydrothermal extract may be further fractionated using one or more solvents selected from the group consisting of n-hexane, methylene chloride, acetone, ethyl acetate and n-butanol. The preparation temperature of the fraction fractionated by using an additional solvent to the extract or extract may be 20 to 50 ℃, but is not limited thereto. Extraction time is not particularly limited, but is preferably extracted within 10 minutes to 1 day, and the extraction device may be a conventional extraction device, ultrasonic grinding extractor or fractionator. The extract thus prepared may be removed by hot air drying, reduced pressure drying, and / or lyophilization, but is not limited thereto. Preferably, the extract may be dried under reduced pressure to remove the solvent.
아울러, 본 발명은 상기 조성물과 약학적으로 허용가능한 담체 또는 식품학적으로 허용가능한 식품보조 첨가제를 포함하는 설사 및 변비를 치료하거나 또는 예방할 수 있는 약제 및 기능성 건강식품을 제공한다.In addition, the present invention provides a pharmaceutical and functional health food that can treat or prevent diarrhea and constipation, comprising the composition and a pharmaceutically acceptable carrier or food acceptable additive.
상기에서 제조된 숙취해소용 조성물이 실질적으로 생체내(in vivo)에서 어떠한 영향을 주는지 알아보기 위하여, 뉴질랜드 토끼 (New zealand rabbit)과 ICR계 생쥐 (ICR mouse)를 대상으로 에탄올과 함께 미나리 추출액을 투여한 후 혈중 에탄올 및 혈중 아세트알데히드 농도를 측정한 결과, 대조군에 비해 미나리 추출물을 투여한 실험군에서 혈중 에탄올 및 혈중 아세트알데히드 농도가 현저히 감소함을 확인하였을 뿐만 아니라(도 1 내지 도 2, 도 4 참조), 그 효능은 농도의존적임을 확인할 수 있었다(도 3 참조). 이는, 본 발명의 조성물이 알코올 섭취 후 대사를 촉진시켜 혈중 에탄올 및 혈중 아세트알데히드 농도를 낮춤으로써, 숙취에 따른 바 람직하지 못한 현상들을 치료 및 예방하는데 효능이 있는 약제 및 기능성 건강식품으로 이용될 수 있음을 의미한다.In order to find out how the hangover composition prepared above substantially affects in vivo , the buttercup extract with ethanol was prepared in New zealand rabbit and ICR mouse. As a result of measuring the concentration of ethanol and blood acetaldehyde in the blood after administration, it was confirmed that the concentration of ethanol and blood acetaldehyde in blood was significantly reduced in the experimental group to which the buttercup extract was administered compared to the control group (FIGS. 1 to 2 and 4). It was confirmed that the efficacy is concentration-dependent (see Figure 3). This is because the composition of the present invention promotes metabolism after ingesting alcohol, thereby lowering blood ethanol and blood acetaldehyde concentrations, and thus can be used as pharmaceuticals and functional health foods that are effective in treating and preventing undesirable phenomena caused by hangovers. It means that there is.
본 발명에 있어서, 상기 조성물은 단독으로 사용할 수 있으나, 이에 제한되는 것은 아니며, 상기 조성물에 제형 및 사용목적에 따라 약학적으로 허용가능한 담체나 부형제를 추가적으로 포함시켜 사용할 수 있다. 상기 약학적으로 허용가능한 담체 또는 희석제, 보존제, 안정화제, 습윤제, 유화제, 용해제, 감미제, 착색제, 삼투압 조절제 및 산화방지제 등을 포함하는 부형제는 제형에 따라 통상의 물질을 사용할 수 있으며, 제제화할 경우 충진제, 증량제, 습윤제, 붕해제 또는 계면활성제 등을 사용할 수 있다. 이때, 대표적인 희석제 또는 부형제로는 물, 덱스트린, 칼슘카보네이드, 락토스, 프로필렌글리콜, 리퀴드 파라틴 및 생리식염수 등을 포함할 수 있다. In the present invention, the composition may be used alone, but is not limited thereto. The composition may additionally include a pharmaceutically acceptable carrier or excipient according to the formulation and purpose of use. Excipients including the pharmaceutically acceptable carriers or diluents, preservatives, stabilizers, wetting agents, emulsifiers, solubilizers, sweeteners, coloring agents, osmotic pressure control agents and antioxidants can be used in the conventional formulations, if formulated Fillers, extenders, wetting agents, disintegrating agents or surfactants may be used. At this time, representative diluents or excipients may include water, dextrin, calcium carbonate, lactose, propylene glycol, liquid paratin and physiological saline.
또한, 상기 조성물은 경구 또는 비경구로 투여할 수 있으며, 그의 제형은 사용목적에 따라 경고제(PLASTERS), 과립제(GRANULES), 로션제(LOTIONS), 산제(POWDERS), 시럽제(SYRUPS), 액제(LIQUIDS AND SOLUTIONS), 에어로솔제(AEROSOLS), 연고제(OINTMENTS), 유동엑스제(FLUIDEXTRACTS), 유제(EMULSIONS), 캅셀제(CAPSULES) 또는 환제(PILLS) 등으로 이용할 수 있으며, 이에 제한되는 것은 아니다. 덧붙여, 본 발명의 조성물은 당해 기술 분야의 공지된 방법 또는 레밍턴의 문헌[Remington's Pharmaceutical Science(최신판), Mack Publishing Company, Easton, PA)에 기재된 방법을 이용하여 바람직하게 제형화될 수 있다. 상기 조성물의 투여량 또는 사용량은 환자의 체중, 연령, 성별, 건강상태, 식이, 투여시간, 투여방법, 배설률 및 질환의 중증도 등을 고려하여 사용하는 것이 바람직하며, 투여량은 통상적으로는 1 내지 250mg/kg, 투여횟수는 하루에 1회 내지 수회, 바람직하게는 성인(70Kg)의 경우 1일 0.5~2g, 1일 3회 또는 4회로 나누어 투여할 수 있으며, 투여기간도 특별히 제한되는 것은 아니다. 또한, 상기 조성물은 단독으로 경구 투여하는 방법 이외에, 임의의 음식물에 첨가하여 사용할 수 있다. In addition, the composition can be administered orally or parenterally, the formulation of the formulation (PLASTERS), granules (GRANULES), lotions (LOTIONS), powders (POWDERS), syrups (SYRUPS), liquid ( LIQUIDS AND SOLUTIONS), AEROSOLS, OINTMENTS, FLUIDEXTRACTS, Emulsions, EMULSIONS, CAPSULES or PILLS, but are not limited thereto. In addition, the compositions of the present invention may be preferably formulated using methods known in the art or described in Remington's Pharmaceutical Science (latest version), Mack Publishing Company, Easton, PA. The dosage or amount of the composition is preferably used in consideration of the body weight, age, sex, health condition, diet, time of administration, administration method, excretion rate and severity of the disease, the dosage is usually 1 to 250mg / kg, frequency of administration can be administered once or several times a day, preferably in the case of adult (70Kg) divided into 0.5 ~ 2g, three times or four times a day, the administration period is not particularly limited. . In addition, the composition may be used in addition to any food, in addition to oral administration alone.
또한, 본 발명의 조성물은 소화 및 정장, 비만, 당뇨병 및 고지혈증뿐 아니라 설사 및 변비 억제에 유용하며 독성과 부작용이 없어 장기간 복용할 수 있기 때문에, 기능성 건강식품 또는 건강식품 보조제 등으로 유용하게 사용될 수 있다. 이때, 상기 건강식품으로는 약제, 식품 및 음료 등을 포함할 수 있으며, 구체적으로는 각종 식품류, 캔디, 초콜릿, 음료, 껌, 차, 비타민복합체, 건강보조 식품류 등이 있고, 분말, 과립, 정제, 캡슐 또는 음료의 형태로 사용될 수 있다. 또한, 상기 식품 또는 음료에 첨가되는 상기 조성물의 양은 특별히 제한되는 것은 아니나, 전체 식품 중량의 1 내지 80 중량%, 바람직하게는 1 내지 20 중량%로 사용할 수 있고, 건강 음료의 경우, 100ml 당 0.1 내지 10g, 바람직하게는 0.5 내지 2g의 비율로 사용할 수 있다.In addition, the composition of the present invention is useful for suppressing digestion and intestine, obesity, diabetes and hyperlipidemia, as well as diarrhea and constipation, and can be used as a functional health food or health food supplement because it can be taken for a long time without toxicity and side effects. have. In this case, the health food may include drugs, food and beverages, and specifically, various foods, candy, chocolate, drinks, gum, tea, vitamin complexes, health supplements, and the like, powders, granules, tablets It can be used in the form of capsules or beverages. In addition, the amount of the composition added to the food or beverage is not particularly limited, but may be used in 1 to 80% by weight, preferably 1 to 20% by weight of the total food weight, in the case of a health beverage, 0.1 per 100ml To 10 g, preferably 0.5 to 2 g.
이때, 상기 기능성 건강식품은 본 발명의 조성물과 함께 식품학적으로 허용가능한 식품보조 첨가제를 추가적으로 포함할 수 있다. 예를 들어, 상기 조성물을 포함하는 건강 음료에 사용되는 액체 성분은 특별히 제한되는 것은 아니며, 통상적인 음료와 같이 여러 가지의 향미제 또는 천연 탄수화물 등을 추가적인 성분으로 함유할 수 있다. 이때, 상기 천연 탄수화물의 예로는 포도당, 과당 등의 모노사카 라이드; 말토오스, 수크로오스 등의 디사카라이드; 덱스트린, 시클로덱스트린 등의 폴리사카라이드 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알코올 등이 있다. 또한, 상기 향미제로는 천연 향미제[타우마틴, 스테비아 추출물(예를 들면, 바우디오시드 A, 글리시르히진(glycyrrhizin) 등] 또는 합성 향미제(사카린, 아스프르탐 등)를 사용할 수 있다. 이때, 상기 천연 탄수화물의 비율은 건강음료 조성물 100ml 당 0.1 내지 20g, 바람직하게는 0.5 내지 2g이다.At this time, the functional health food may further include a food supplement acceptable food additive with the composition of the present invention. For example, the liquid component used in the health beverage containing the composition is not particularly limited, and may include various flavors or natural carbohydrates as additional ingredients, such as conventional drinks. At this time, examples of the natural carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; Conventional sugars such as polysaccharides such as dextrin, cyclodextrin and the like and sugar alcohols such as xylitol, sorbitol, and erythritol. In addition, the flavoring agent may be a natural flavoring agent (tauumatin, stevia extract (e.g., Baudioside A, glycyrrhizin, etc.) or synthetic flavoring agents (saccharin, aspartame, etc.). At this time, the ratio of the natural carbohydrate is 0.1 to 20g, preferably 0.5 to 2g per 100ml of the health beverage composition.
덧붙여, 상기 기능성 건강식품은 여러 가지의 영양제, 비타민, 광물(전해질), 천연 또는 합성 풍미제, 착색제 또는 충진제(치즈, 초콜릿 등), 펙트산 또는 그의 염, 알긴산 또는 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올 또는 탄산음료에 사용되는 탄산화제 등을 함유할 수 있으며, 이외에도 천연과일 또는 야채 음료를 제조하기 위해 과육을 함유할 수도 있다. 이때, 상기 성분들은 단독 또는 조합하여 사용될 수 있다. 또한, 상기 첨가제의 비율은 특별히 제한되는 것은 아니나, 기능성 건강식품 100 중량% 당 1 내지 20 중량%의 범위에서 선택할 수 있다. In addition, the functional health food includes various nutrients, vitamins, minerals (electrolytes), natural or synthetic flavors, colorants or fillers (such as cheese and chocolate), pectic acid or salts thereof, alginic acid or salts thereof, organic acids, protective properties. It may contain colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, carbonation agents used in alcoholic or carbonated beverages, and the like, and may also contain flesh to produce natural fruit or vegetable beverages. At this time, the components may be used alone or in combination. In addition, the ratio of the additive is not particularly limited, but may be selected in the range of 1 to 20% by weight per 100% by weight of the functional health food.
이하, 본 발명의 구체적인 방법을 실시예를 들어 상세히 설명하고자 하지만 본 발명의 권리범위는 이들 실시예에만 한정되는 것은 아니다.Hereinafter, the specific method of the present invention will be described in detail with reference to Examples, but the scope of the present invention is not limited only to these Examples.
실시예Example 1: 미나리의 1: buttercup 열수Hydrothermal 추출물 제조 Extract manufacturer
경북 청도군 청도읍 평양리에서 구입한 미나리를 상온에서 1주일간 음건한 후 600g을 취하여 분쇄한 후 증류수 6 L를 가하여 100℃에서 1시간~3시간 환류 추출하고, 이를 증발 건조시켜 추출물의 양을 측정한 결과 27~31%의 수율로 164.0g~185.8g을 수득하였다(표 1). 이렇게 얻은 미나리 열수 추출물을 HPLC로 분석한 결과, 지표물질인 페르시카린(persicarin)의 함량은 0.23%이었다. 이 때 사용한 HPLC는 시마쯔 엘씨-10에이 듀얼 펌프(Shimadzu LC-10A dual pump), 에스씨엘-10브이피 콘트롤러(SCL-10vp Controller), 에스아이엘-에이에프 오토인젝터(SIL-AF autoinjector), 에스피디-엠 10Avp 다이오드 어레이 디텍터(SPD-M 10Avp diode array detector)로 구성된 것을 사용하였으며, 심-팍 씨엘씨-오디에스(Shim-pak CLC-ODS)를 통해 유출용매를 6ml/min의 유속으로 하여 유출하면서 253nm 파장에서 유출액을 검출하였다. 유출 용매로는 A 액으로 메탄올(methanol), B 액으로 증류수를 사용하였으며, 이 두 용매의 농도 경사를 이용하여 유출시켰다.After drying the Minari purchased from Pyongyang-ri, Cheongdo-eup, Cheongdo-gun, Gyeongbuk, Korea for 1 week, take 600g and crush it. 164.0g-185.8g was obtained by the yield of 27-31% (Table 1). As a result of analyzing the hot water extract of Buttercup hot water by HPLC, the content of persicarin as an indicator was 0.23%. The HPLC used at this time was Shimadzu LC-10A dual pump, SCL-10vp Controller, SIL-AF autoinjector, and SPD. The SPD-M 10Avp diode array detector was used, and the outflow solvent was flowed through the Shim-pak CLC-ODS at a flow rate of 6 ml / min. The effluent was detected at a wavelength of 253 nm. Methanol was used as the A liquid and distilled water was used as the B liquid, and the solvent was distilled out using the concentration gradient of the two solvents.
실시예Example 2: 미나리 2: buttercup 열수Hydrothermal 추출물의 에탄올 대사에 미치는 활성 Activity on Ethanol Metabolism of Extracts
미나리 추출물 투여에 따른 혈중 에탄올 농도의 변화를 관찰하기 위해, 체중 2.5 kg 내외의 뉴질랜드 흰색 토끼(Newzealand white rabbit, n=9)를 미나리 열수 추출물(수율 27.4%) 10%가 포함된 20% 에탄올 용액 투여군과 미나리 추출물 대신 생리식염수 10%가 포함된 20% 에탄올 용액 투여군으로 나누어, 체중 kg당 500 ul 씩을 귀정맥으로 투여 한 후 5분, 1시간, 3시간 및 5시간에 걸쳐 혈장 에탄올 농도를 측정하였다. 이 때 대조약물로 메타독신(metadoxine, 상품명; 알도텔)을 사용하였으며 체중 kg당 50 mg을 같은 방법으로 투여하였다. 실험은 첫 번째는 대조군, 미나리 추출물 투여군, 메타독신 투여군이 각 3마리가 되게 하였으며 일주일 단위로 군을 순차적으로 바꾸어 실험을 시작하여 각 군의 개체수는 9마리가 되도록 하였으며 통계 처리는 페어드 앤드 논-페어드 샘플(paired and non-paired sample)로 처리하였다. 이 때 혈장 에탄올 농도는 미국 시그마사의 혈중 에탄올 측정용 키트를 구입하여 사용하였다. In order to observe the change in blood ethanol concentration according to the administration of the buttercup extract, a Newzealand white rabbit (n = 9) weighing about 2.5 kg in body weight and a 20% ethanol solution containing 10% of buttercup hydrothermal extract (yield 27.4%) Plasma ethanol concentration was measured over 5 minutes, 1 hour, 3 hours and 5 hours after administering 500 ul per kg body weight to the vein in the 20% ethanol solution containing 10% physiological saline instead of the administration group and buttercup extract. It was. At this time, metadoxine (metadoxine (trade name; Aldotel)) was used as a control drug and 50 mg / kg body weight was administered in the same manner. In the first experiment, the control group, the buttercup extract group, and the metadoxine group were three dogs, and the group was changed sequentially every week to start the experiment so that the population of each group was nine. Treated with paired and non-paired samples. At this time, the plasma ethanol concentration was used by purchasing a blood ethanol measurement kit of Sigma, USA.
그 결과, 투여 5분 후 혈장 에탄올 농도는 미나리 추출물과 대조군이 각각 215±11(평균값±표준오차, 이하 동일)mg/dl와 213±13mg/dl로 차이가 없었으나, 1시간 후에는 미나리 추출물 투여군은 111±5.0mg/dl로서 대조군의 122±6.1mg/dl에 비하여 9% 가량 감소하였으며(p<0.001), 3시간 후에는 50±2.3mg/dl으로서 대조군의 69±3.3mg/dl에 비하여 28% 낮았으며(p<0.001), 5시간 후에는 33±2.1mg/dl로서 대조군의 54±2.7mg/dl에 비하여 39%나 감소(p<0.001)함을 관찰하였다. 현재 시판되고 있는 메타독신 투여 군에서는 에탄올 투여 5분 후에 216±15mg/dl, 1시간 후에 108±6.2mg/dl, 3시간 후에 48±2.5mg/dl 및 5시간 후에 30±3.0mg/dl로 미나리 추출물 투여군과 유사한 혈중 알코올 농도 제거 효능을 보였다. 따라서 미나리 추출물 투여군과 메타독신 투여군은 투여 3시간 만에 운전이 가능한 법정알코올 농도 0.05% 이하로 알코올 농도가 감소하였지만 대조군은 2시간이 더 경과한 5시간 후에도 54±2.7mg/dl로 법정알코올 농도를 초과하였다(도 1). As a result, the plasma ethanol concentration after 5 minutes of administration was no difference between the buttercup extract and the control group, 215 ± 11 mg / dl and 213 ± 13 mg / dl, respectively. The treatment group was 111 ± 5.0mg / dl, which was 9% lower than the control group's 122 ± 6.1mg / dl (p <0.001). After 3 hours, it was 50 ± 2.3mg / dl and the control group was 69 ± 3.3mg / dl. It was 28% lower than the control group (p <0.001), and after 5 hours, it was 33 ± 2.1 mg / dl, which was 39% lower than the control group's 54 ± 2.7 mg / dl (p <0.001). In the currently available metadoxin-administered group, 216 ± 15mg / dl after 5 minutes of ethanol administration, 108 ± 6.2mg / dl after 1 hour, 48 ± 2.5mg / dl after 3 hours and 30 ± 3.0mg / dl after 5 hours Similar to the buttercup extract group, the blood alcohol concentration removal effect was shown. Therefore, the concentration of alcohol decreased to 0.05% of legal alcohol that could be operated after 3 hours of administration of Buttercup extract group and metadoxin, but the control group had a concentration of 54 ± 2.7mg / dl after 5 hours. Exceeded (FIG. 1).
실시예Example 3: 미나리 3: buttercup 열수Hydrothermal 추출물의 2차 분획 Secondary fraction of extract
미나리의 열수 추출물을 2 L의 증류수에 현탁한 후 동량의 n-헥산으로 3회 반복 추출하여 n-헥산 가용부를 한데모아 용매를 감압 농축하여 n-헥산 분획으로 하였다. 남은 물층은 1.5 L가 될 때까지 농축하고 동량의 메틸렌클로라이드(methylene chloride)를 가해 3회 반복 추출하고, 추출액을 한데 모아 용매를 농축 제거하여 메틸렌클로라이드 분획으로 하였다. 나머지 물층을 다시 1.2 L가 되도록 농축한 후 동량의 에틸아세테이트(ethyl acetate)를 가해 3회 반복 추출하고, 추출액을 한데 모아 에틸아세테이트 분획으로 하였다. 나머지 물층은 다시 1 L가 되도록 농축한 후에 동량의 n-부탄올을 가해 3회 반복 추출하고, 추출액을 한데 모아 용매를 농축, 제거하여 n-부탄올 분획으로 하였다. 나머지 남은 물층은 완전히 농축하여 물분획으로 하였다. The hot water extract of Buttercup was suspended in 2 L of distilled water, and extracted three times with the same amount of n-hexane. The n-hexane soluble part was collected, and the solvent was concentrated under reduced pressure to obtain an n-hexane fraction. The remaining water layer was concentrated to 1.5 L, and the same amount of methylene chloride was added and extracted three times. The extracts were combined and the solvent was concentrated to remove the methylene chloride fraction. The remaining water layer was concentrated to 1.2 L again, and then the same amount of ethyl acetate was added and extracted three times. The extracts were put together to form an ethyl acetate fraction. The remaining water layer was concentrated to 1 L again, followed by extraction three times with the same amount of n-butanol, and the extracts were collected, and the solvent was concentrated and removed to obtain n-butanol fraction. The remaining water layer was completely concentrated to give a water fraction.
실시예Example 4: 미나리 4: buttercup 열수Hydrothermal 추출물의 2차 분획의 에탄올 대사에 미치는 활성 Activity on Ethanol Metabolism of Secondary Fractions of Extracts
상기 실시예 3에서 수득한 5종의 미나리 열수 추출물의 2차 분획 시료에 대하여 ICR계 마우스 (체중 30 그램 내외)를 대상으로 에탄올 대사에 미치는 활성을 조사하였다. ICR계 마우스 수컷에게 30% 에탄올을 체중 kg 당 8 ml를 경구 투여하면서, 미나리 열수 추출물의 각 2차 분획들을 체중 kg 당 추출 전 음건한 미나리 양으로 200mg이 되도록 경구 투여 하였으며, 혈중 에탄올 농도는 투여 2시간 후에 측정하였다. Secondary fraction samples of the five kinds of Buttercup hot water extracts obtained in Example 3 were examined for ethanol metabolism in ICR mice (about 30 gram body weight). While administering 30% ethanol or 8 ml / kg body weight to ICR mice, each of the secondary fractions of the buttercup hydrothermal extract was orally administered to 200 mg in the dry parsley weight per kg body weight, and blood ethanol concentration was administered. Measured after 2 hours.
그 결과, 혈중 에탄올 농도가 n-헥산 분획 투여군에서는 68±8.1mg/dl, 메틸렌클로라이드 분획 투여군에서는 83±1.9mg/dl, 에틸아세테이트 분획 투여군에서는 70±14.3mg/dl, n-부탄올 분획 투여군에서는 15±1.1mg/dl, 그리고 대조군에서는70±5.7mg/dl로 나타났다(도 2). 따라서 미나리 열수 추출물의 2차 분획 중 n-부탄올 분획만이 유의성있게 혈중 에탄올 농도를 감소시켰으며, 대조약물인 메타독신투여군에서 얻은 혈중 에탄올 농도 (14±2.9mg/dl)와 유사한 수준이었다. 이는 미나리 열수 추출물의 n-부탄올 분획이 혈중 에탄올 농도를 감소시켜 숙취해소하는 유효 성분이 함유하고 있음을 의미한다.As a result, the blood ethanol concentration was 68 ± 8.1mg / dl in the n-hexane fraction group, 83 ± 1.9mg / dl in the methylene chloride fraction group, 70 ± 14.3mg / dl in the ethyl acetate fraction group, and in the n-butanol fraction group. 15 ± 1.1 mg / dl, and 70 ± 5.7 mg / dl in the control group (Fig. 2). Therefore, only n-butanol fraction in the secondary fraction of Buttercup hot water extract significantly decreased blood ethanol concentration, which was similar to blood ethanol concentration (14 ± 2.9mg / dl) obtained from the control group metadoxin administration group. This means that the n-butanol fraction of the hot water extract of Buttercup contains the active ingredient which decreases the ethanol concentration in the blood and resolves hangover.
미나리 열수 추출물의 n-부탄올 분획의 숙취해소 활성이 농도의존적으로 나타나는지 여부를 확인하고 나아가 유효농도를 조사하기 위하여, ICR계 마우스 수컷에게 30% 에탄올을 체중 kg 당 8 ml를 경구 투여하면서, 미나리 열수 추출물의 n-부탄올 분획을 체중 kg 당 추출 전 음건한 미나리 양으로 각각 25, 50, 100, 200mg이 되도록 경구 투여하고, 투여 2시간 후에 혈중 에탄올 농도를 측정하였다. 그 결과, n-부탄올 분획을 마우스 체중 kg 당 25mg을 투여한 경우에는 혈중 에탄올 농도가 72±8.8mg/dl로 대조군의 혈중 에탄올 농도 77±7.2mg/dl와 차이가 없었으나, 50mg/kg을 투여한 경우에는 혈중 에탄올 농도가 65±7.6mg/dl, 100mg/kg을 투여한 경우에는 51±6.8mg/dl, 200mg/kg을 투여한 경우에는 40±5.9mg/dl으로 나타나 혈중 에탄올 농도의 감소가 n-부탄올 분획의 투여량에 따라 농도의존적으로 감소함을 알 수 있었으며, 특히 200mg/kg에 해당하는 n-부탄올 분획을 투여한 경우 대조약물인 메타독신 투여군에서 얻은 혈중 에탄올 농도 (35±3.8mg/dl)와 유사한 수치를 나타내었다 (도 3). 따라서, 미나리 열수 추출물의 n-부탄올 분획중에 혈중 에탄올 농도를 감소시킬 수 있는 활성물질이 존재하며, 이 활성물질은 농도의존적으로 작용하여 혈중 에탄올 제거 효과를 나타냄을 알 수 있었다. In order to confirm whether the hangover activity of the n-butanol fraction of Buttercup hot water extract is concentration-dependent, and to investigate the effective concentration, the buttercup hot water was orally administered 30 ml of ethanol to 8 ml / kg of body weight. The n-butanol fraction of the extract was orally administered to 25, 50, 100, and 200 mg of dry buttercup per kg body weight, respectively, and the blood ethanol concentration was measured 2 hours after administration. As a result, when the n-butanol fraction was administered at 25 mg / kg of mouse weight, the blood ethanol concentration was 72 ± 8.8mg / dl, which was not different from the blood ethanol concentration 77 ± 7.2mg / dl in the control group. In the case of administration, the blood ethanol concentration was 65 ± 7.6 mg / dl, 100 mg / kg was 51 ± 6.8 mg / dl, and 200 mg / kg was 40 ± 5.9 mg / dl. It was found that the decrease was dependent on the dose depending on the dose of the n-butanol fraction. Especially, when the n-butanol fraction corresponding to 200 mg / kg was administered, the serum ethanol concentration (35 ± 3.8 mg / dl) (Figure 3). Therefore, it was found that there is an active substance which can reduce the concentration of ethanol in blood in the n-butanol fraction of the hot water extract of Buttercup, and this active substance has a concentration-dependent effect on the removal of blood ethanol.
실시예Example 5: 미나리 5: buttercup 열수Hydrothermal 추출물 및 이의 n- Extracts and n- 부탄올Butanol 분획의 숙취해소 활성 Hangover Relief Activity of Fractions
상기 실시예 4에서 미나리 열수 추출물의 n-부탄올 분획이 강한 에탄올 제거 효과를 보였으므로, 미나리 열수 추출물 및 이의 n-부탄올 분획이 숙취해소 활성을 나타내는지 여부를 확인하기 위해, 숙취를 유발하는 아세트알데히드의 혈중 농도를 관찰하였다. 구체적으로 ICR계 마우스 수컷에게 30% 에탄올을 체중 kg 당 8 ml를 경구 투여하면서, 미나리 열수 추출물 및 이의 n-부탄올 분획을 체중 kg 당 추출 전 음건한 미나리 양으로 200mg이 되도록 경구 투여하고, 투여 2시간 후에 혈중 에탄올 농도 및 혈중 아세트알데히드 농도를 측정하였다. 이 때 혈중 아세트알데히드 농도는 베링거 만하임 사의 측정용 키트를 사용하였다. Since the n-butanol fraction of the Buttercup hot water extract in Example 4 showed a strong ethanol removal effect, in order to determine whether the Buttercup hot water extract and its n-butanol fraction exhibit hangover activity, acetaldehyde causing hangover The blood concentration of was observed. Specifically, oral administration of 30% ethanol to 8 ml / kg body weight of male ICR mice, oral administration of the Buttercup hydrothermal extract and its n-butanol fraction to 200 mg in the dry amount of parsley before extraction per kg of body weight, administration 2 After time, blood ethanol concentration and blood acetaldehyde concentration were measured. At this time, the concentration of acetaldehyde in blood was measured by the Boehringer Mannheim measuring kit.
그 결과, 미나리 열수 추출물 투여군의 혈중 에탄올 농도는 42±3.9mg/dl로 대조군의 75±8.2mg/dl에 비하여 44% 감소하였고, n-부탄올 2차 분획 투여군에서는 22±3.0mg/dl로 70%나 감소하였으며, 대조약물인 메타독신 투여군에서는 25±2.8mg/dl로 67% 감소하였다(도 4a). As a result, the blood ethanol concentration of the Buttercup hot water extract administration group was 42 ± 3.9 mg / dl, 44% lower than 75 ± 8.2mg / dl of the control group, and 70 ± 22 ± 3.0mg / dl in the n-butanol secondary fraction administration group. The percentage was decreased by 67% at 25 ± 2.8 mg / dl in the control group metadoxin (Figure 4a).
한편, 혈중 아세트알데히드 농도는 미나리의 열수 추출물 투여군에서 0.325±0.031mg/dl로 나타나 대조군에서 얻어진 0.425±0.039mg/dl에 비하여 24% 감소하였으며, n-부탄올 2차 분획 투여군에서는 0.305±0.029mg/dl으로 측정되어 28%나 감소하였다. 그러나 대조약물인 메타독신 투여군에서는 0.355±0.025mg/dl로 관찰되어 16% 정도만 감소하는 경향을 보였다 (도 4b). On the other hand, blood acetaldehyde concentration was 0.325 ± 0.031mg / dl in the hot water extract administration group of Buttercup, which was reduced by 24% compared to 0.425 ± 0.039mg / dl obtained in the control group, and 0.305 ± 0.029mg / in the n-butanol secondary fraction administration group. It was measured in dl and decreased by 28%. However, in the control group metadoxin-treated group was observed 0.355 ± 0.025 mg / dl showed a tendency to decrease only 16% (Fig. 4b).
일반적으로 혈중 에탄올 제거가 빠를수록 혈중의 아세트알데히드 농도는 증가하는 양상을 보이므로, 실제의 혈중 아세트알데히드 농도는 대조군에 비하여 미나리 열수 추출물 투여군의 경우 47%, n-부탄올 2차 분획 투여군의 경우 58%, 메타독신 투여군의 경우 50%의 아세트알데히드 제거 효과를 가지는 것으로 추산할 수 있다. In general, the faster the ethanol removal, the higher the acetaldehyde concentration in the blood. Thus, the actual acetaldehyde concentration in the blood was 47% compared to the control group compared to the control group, and 47% compared to the control group, but it was 58 in the n-butanol secondary fraction group. %, Metadoxin can be estimated to have a 50% acetaldehyde removal effect in the group.
실시예Example 5: 미나리 5: buttercup 열수Hydrothermal 추출물 및 이의 n- Extracts and n- 부탄올Butanol 분획 투여에 따른 조직 변화 관찰 Observation of tissue change according to fractional administration
미나리 열수 추출물 및 이의 n-부탄올 분획의 투여에 따른 급성 부작용의 발생 여부를 관찰하기 위해, 실시예 4에서의 투여량을 10배로 늘려 동일한 방법으로 ICR계 마우스에 투여하고, 마우스의 뇌, 소뇌, 심장, 간, 신장, 소장, 췌장 및 골격근 등의 각 조직을 절취하여 조사하였으나, 각 조직에서 정상 대조군과 비교하여 유의한 조직 변화를 관찰할 수 없었다.In order to observe the occurrence of acute side effects according to the administration of the Buttercup hot water extract and its n-butanol fraction, the dose in Example 4 was increased by 10 times and administered to ICR mice in the same manner, and the brain, cerebellum, Each tissue such as heart, liver, kidney, small intestine, pancreas, and skeletal muscle was cut and examined, but no significant tissue changes were observed in each tissue compared with the normal control group.
이상, 실시예를 통하여 설명한 바와 같이, 본 발명의 미나리 추출물, 바람직하게는 열수 추출물 또는 이의 n-부탄올 분획은 혈중 에탄올 및 혈중 아세트알데히드 농도를 감소시켜 숙취 예방 및 해소에 활성을 나타내며, 급성 부작용이 관찰되 지 않으므로, 미나리 추출물을 포함하는 약제 및 기능성 건강식품은 효과적인 숙취해소용 조성물로 사용될 수 있으며 특히 천연식품의 특정성분을 추출 생성함으로서 인체에 무해하여 부작용이 전혀 없으면서도 숙취예방과 해소에 탁월한 효과를 발휘할 수 있고 단일성분의 다량 투여하는 경우에 비하여 상대적으로 독성이 적고, 화학적으로 합성되어 판매되는 약물에 비하여 중독성이 없을 것으로 기대되므로, 인체에 무해한 숙취 예방 및 해소제를 제공할 수 있는 매우 뛰어난 효과가 있으므로 식품, 의약품 산업상 매우 유용한 발명인 것이다.As described above, as described through the examples, the buttercup extract, preferably the hydrothermal extract or n-butanol fraction thereof of the present invention shows activity in preventing and resolving hangover by reducing blood ethanol and blood acetaldehyde concentration, Since it is not observed, pharmaceuticals and functional health foods containing buttercup extracts can be used as effective hangover-removing compositions. Especially, by extracting and producing certain ingredients of natural foods, they are harmless to humans and have excellent side effects without hangovers. It is expected to be effective and relatively less toxic than a large dose of a single component, and not expected to be addictive compared to chemically synthesized and marketed drugs, which can provide a hangover prevention and remedy that is harmless to the human body. Has excellent effect, so food, pharmaceutical acid The very useful inventions.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060102442A KR20080035853A (en) | 2006-10-20 | 2006-10-20 | A composition having protective function from alcoholic hangover comprising dropwort extract as active ingredient and functional health food using the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060102442A KR20080035853A (en) | 2006-10-20 | 2006-10-20 | A composition having protective function from alcoholic hangover comprising dropwort extract as active ingredient and functional health food using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20080035853A true KR20080035853A (en) | 2008-04-24 |
Family
ID=39574586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060102442A KR20080035853A (en) | 2006-10-20 | 2006-10-20 | A composition having protective function from alcoholic hangover comprising dropwort extract as active ingredient and functional health food using the same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20080035853A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100977583B1 (en) * | 2008-04-14 | 2010-08-24 | 전남대학교산학협력단 | Ethanol extracts and caffeic acid from Ocnanthe javanica DC. having hepatoprotective effect, the method for preparing thereof and functional foodstuff comprising the same |
KR101034986B1 (en) * | 2010-12-17 | 2011-05-17 | 김춘성 | Composition comprising the mixed herbal extract for relieving hangover |
KR101308882B1 (en) * | 2011-11-18 | 2013-09-23 | 주식회사 엠에스씨 | Manufacturing Method of Dropwort Liquid |
-
2006
- 2006-10-20 KR KR1020060102442A patent/KR20080035853A/en not_active Application Discontinuation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100977583B1 (en) * | 2008-04-14 | 2010-08-24 | 전남대학교산학협력단 | Ethanol extracts and caffeic acid from Ocnanthe javanica DC. having hepatoprotective effect, the method for preparing thereof and functional foodstuff comprising the same |
KR101034986B1 (en) * | 2010-12-17 | 2011-05-17 | 김춘성 | Composition comprising the mixed herbal extract for relieving hangover |
KR101308882B1 (en) * | 2011-11-18 | 2013-09-23 | 주식회사 엠에스씨 | Manufacturing Method of Dropwort Liquid |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5937596B2 (en) | Urushi extract with increased content of active flavonoid compound and method for producing the same | |
KR102132655B1 (en) | Composition containing chrysanthemum zawadskii extract | |
KR101782848B1 (en) | Composition for eliminating hangover and preventing, improving or treating alcoholic gastrointestinal diseases comprising Dolichos lablab extract as effective component | |
KR101382099B1 (en) | Anticonvulsive compositions comprising aster glehni extract, fractions thereof, or compounds isolated from thereform | |
JP5275251B2 (en) | Composition comprising an extract of a combined herb for preventing and treating liver disease | |
KR20120003693A (en) | Anti-obesity composition comprising red grape extracts, green tea extracts, soybean extracts, and l-carnitine | |
KR102064651B1 (en) | Composition for preventing or improving diabetes mellitus comprising momrdica charantia (l.) extract, chrysanthemum zawadskii var. latilobum and paeonia lactiflora extract as an effective ingredient | |
KR100976241B1 (en) | Extract of sedum sarmentosum for alcohol oxidation and relieves hangover | |
KR20080035853A (en) | A composition having protective function from alcoholic hangover comprising dropwort extract as active ingredient and functional health food using the same | |
KR20140137289A (en) | Composition comprising an extract of Alpinia officinarum Hance for preventing and treating hangover or liver disease | |
KR101731152B1 (en) | Anti-diabetic composition containing the extract of actinidia arguta leaves or fractions thereof | |
KR101536974B1 (en) | Composition for preventing and improving diabetes comprising extracts of Momordica charantia, Corni fructus, Schizandra chinensis and Jujube | |
KR102239066B1 (en) | Composition for preventing, ameliorating or treating metabolic diseases comprising mixture of plant extract as effective component | |
KR20140108104A (en) | Compositions comprising the combined extract of Artemisia iwayomogi and Curcuma longa for treating, inhibiting or preventing obesity-related disease | |
KR101910099B1 (en) | Compositions for improving lipid metabolism or anti-obesity as an active ingredient extracted from an immature persimmon by pressurized hydrothermal method | |
KR101854180B1 (en) | Health function food for preventing or improving liver injury comprising extract of citrus preicarp | |
JP2007008883A (en) | Composition having blood glucose level-lowering action | |
KR102563745B1 (en) | Pharmaceutical composition for preventing or treating obesity having garcinia cambogia extract and health functional food having the same | |
CN108720013A (en) | The formula and processing technology of the health food of one group of Soboring-up liver-protecting being made of fructose and tea extract | |
KR102210082B1 (en) | A pharmaceutical composition comprising HM-chromanone which activates AMPK as an active ingredient | |
KR102500342B1 (en) | Composition for preventing, ameliorating or treating hypercholesterinemia containing Cannabis sativa stem extract as effective component | |
US20210393730A1 (en) | Herbal composition for reducing uric acid and the use in reducing uric acid, body fat, and blood glucose thereof | |
KR20240032213A (en) | Composition for preventing, ameliorating or treating hypercholesterinemia comprising Acer palmatum Thunb leaf extract as effective component | |
KR100473529B1 (en) | Composition comprising an extract of sungisan crude drug complex as an effective ingredient for preventing and treating diabetes | |
CA3226434A1 (en) | Composition comprising horse chestnut extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E90F | Notification of reason for final refusal | ||
E601 | Decision to refuse application |